Payment overview · 2025
General Payments
$1,348.70
68 reported records · 20 companies
Healthcare provider profile · identity verified
Mark B. Schabbing, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PERRYVILLE, MO · NPI 1861584534
Verified facts
What the public records show
CMS Open Payments records show Mark B. Schabbing, M.D. received $1,348.70 in general payments during 2025 across 68 reported records.
ABBVIE INC. accounted for 40.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Farxiga, Gemtesa, Jardiance, Kerendia, Mounjaro, Ozempic, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 234 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $545.38 | 40.4% | 25 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $110.04 | 8.2% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $94.04 | 7.0% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $85.17 | 6.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $81.95 | 6.1% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $58.66 | 4.3% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$57.87 | 4.3% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $46.18 | 3.4% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $40.41 | 3.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.42 | 2.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.58 | 2.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.53 | 2.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.06 | 1.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.41 | 1.4% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $18.78 | 1.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.19 | 1.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.28 | 1.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.94 | 1.2% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $14.98 | 1.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.83 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,348.70 | 68 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $291.76 | 12 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $139.98 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $113.64 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $110.04 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $101.45 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $94.04 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $91.56 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $81.95 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $58.66 | 3 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $57.87 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $50.74 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $46.18 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $40.41 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $32.42 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $30.58 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $28.53 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $28.53 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.06 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.06 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.06 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.41 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $19.41 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.94 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.83 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 30 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 115 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 147 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 67 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
115 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
147 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
30 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
43 | 14 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
64 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
147 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
67 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
234 | 37 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 765 | 200 |
| Amlodipine Besylate | Amlodipine Besylate | 746 | 179 |
| Levothyroxine Sodium | Levothyroxine Sodium | 615 | 120 |
| Lisinopril | Lisinopril | 589 | 168 |
| Pantoprazole Sodium | Pantoprazole Sodium | 308 | 81 |
| Losartan Potassium | Losartan Potassium | 305 | 84 |
| Carvedilol | Carvedilol | 300 | 68 |
| Sertraline Hcl | Sertraline Hcl | 247 | 50 |
| Eliquis | Apixaban | 234 | 37 |
| Gabapentin | Gabapentin | 233 | 65 |
| Metoprolol Tartrate | Metoprolol Tartrate | 233 | 56 |
| Furosemide | Furosemide | 229 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 220 | 55 |
| Metformin Hcl Er | Metformin Hcl | 219 | 61 |
| Omeprazole | Omeprazole | 198 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 191 | 54 |
| Allopurinol | Allopurinol | 180 | 43 |
| Warfarin Sodium | Warfarin Sodium | 174 | 15 |
| Potassium Chloride | Potassium Chloride | 168 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 160 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 154 | 46 |
| Metformin Hcl | Metformin Hcl | 153 | 35 |
| Jardiance | Empagliflozin | 147 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 143 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 137 | 39 |
| Simvastatin | Simvastatin | 132 | 38 |
| Lovastatin | Lovastatin | 126 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 117 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 116 | 31 |
| Farxiga | Dapagliflozin Propanediol | 115 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 110 | 25 |
| Spironolactone | Spironolactone | 101 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 38 |
| Glipizide | Glipizide | 97 | 26 |
| Alprazolam | Alprazolam | 96 | 32 |
| Topiramate | Topiramate | 94 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 93 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 92 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 91 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 89 | 20 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 87 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 86 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 24 |
| Buspirone Hcl | Buspirone Hcl | 79 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 78 | 16 |
| Trazodone Hcl | Trazodone Hcl | 78 | 17 |
| Tramadol Hcl | Tramadol Hcl | 77 | 19 |
| Celecoxib | Celecoxib | 75 | 21 |
| Levetiracetam | Levetiracetam | 75 | suppressed |
| Pregabalin | Pregabalin | 72 | 17 |
| Meloxicam | Meloxicam | 67 | 21 |
| Ozempic | Semaglutide | 67 | 13 |
| Xarelto | Rivaroxaban | 64 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 14 |
| Montelukast Sodium | Montelukast Sodium | 54 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 53 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 43 |
| Linzess | Linaclotide | 49 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | 12 |
| Famotidine | Famotidine | 48 | 16 |
| Myrbetriq | Mirabegron | 47 | 12 |
| Lamotrigine | Lamotrigine | 44 | suppressed |
| Ketoconazole | Ketoconazole | 43 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 11 |
| Risperidone | Risperidone | 43 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | 14 |
| Calcitriol | Calcitriol | 42 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 40 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 39 | suppressed |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 11 |
| Clonazepam | Clonazepam | 37 | suppressed |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Trulicity | Dulaglutide | 36 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 35 | suppressed |
| Glimepiride | Glimepiride | 35 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 34 | suppressed |
| Chlorthalidone | Chlorthalidone | 34 | 18 |
| Oxcarbazepine | Oxcarbazepine | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | 12 |
| Diazepam | Diazepam | 32 | suppressed |
| Digoxin | Digoxin | 32 | suppressed |
| Prednisone | Prednisone | 32 | 25 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 30 | 30 |
| Humalog Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Gemtesa | Vibegron | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 26 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Methotrexate | Methotrexate Sodium | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 20 |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Cefdinir | Cefdinir | 20 | 18 |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 18 |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 17 |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 18 | suppressed |
| Kerendia | Finerenone | 18 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 15 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Felodipine Er | Felodipine | 14 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | 13 |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Probenecid | Probenecid | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,348.70 · 68 records | ABBVIE INC. | ABRYSVO, AREXVY, BEXSERO, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FARXIGA, GEMTESA, INCEPTIV, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REXULTI, Rybelsus, SHINGRIX, SPRAVATO, UBRELVY, UZEDY, VOQUEZNA, VRAYLAR, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error